Gsk (GSK) Change in Accured Expenses (2009 - 2026)

Gsk (GSK) posted Change in Accured Expenses of $773.4 million for Q3 2026, up 202.72% quarter-over-quarter from -$752.9 million in Q4 2025.

Analysis

Gsk (GSK) Change in Accured Expenses (2009 - 2026) Analysis & Trends

Gsk (GSK) has 10 years of Change in Accured Expenses data on file, last reported at $773.4 million in Q3 2026.

For the quarter ending Q3 2026, Change in Accured Expenses changed N/A year-over-year to $773.4 million; the trailing twelve-month figure through Sep 2026 stood at $1.1 billion (changed N/A YoY), and the FY2015 full-year result was $2.5 billion, up 111.5% from the prior year.
Change in Accured Expenses was $773.4 million for Q3 2026 at Gsk, up from -$752.9 million in the prior quarter.
In the past five years, Change in Accured Expenses ranged from a high of $773.4 million in Q3 2026 to a low of -$752.9 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Asml Holding	618.86 Bn	602.88 Bn	5.90 Bn	-
2	Hsbc Holdings	361.40 Bn	361.40 Bn	-	-
3	General Electric	329.38 Bn	320.03 Bn	6.95 Bn	-
4	Astrazeneca	253.73 Bn	248.44 Bn	12.86 Bn	-
5	Citigroup	228.07 Bn	-2,074.24 Bn	24.75 Bn	-
6	Bhp	216.09 Bn	197.55 Bn	-	679.00 Mn
7	Rio Tinto	203.71 Bn	199.33 Bn	-	-
8	Diageo	197.36 Bn	195.32 Bn	-	-
9	Unilever	139.15 Bn	132.12 Bn	-	-
10	Gsk	101.53 Bn	101.53 Bn	15.97 Bn	773.36 Mn

Historic Data

Download Data